Formosa Laboratories Inc
TWSE:4746
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Inovalis Real Estate Investment Trust
TSX:INO.UN
|
CA |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (13.4), the stock would be worth NT$132.53 (156% upside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 5.2 | NT$51.8 |
0%
|
| 3-Year Average | 13.4 | NT$132.53 |
+156%
|
| 5-Year Average | 16.2 | NT$160.53 |
+210%
|
| Industry Average | 12.6 | NT$124.41 |
+140%
|
| Country Average | 14.3 | NT$141.28 |
+173%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| TW |
|
Formosa Laboratories Inc
TWSE:4746
|
6.2B TWD | 5.2 | 14.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867B USD | 51.6 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.4B USD | 23.4 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 15.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 21.1 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 15.2 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.6B USD | 18.8 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 936 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 10.5 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 17.2 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.8B USD | 10.6 | 16.8 |
Market Distribution
| Min | 0.4 |
| 30th Percentile | 10.4 |
| Median | 14.3 |
| 70th Percentile | 23.6 |
| Max | 8 048.6 |
Other Multiples
Formosa Laboratories Inc
Glance View
Formosa Laboratories, Inc. engages in the research and development of biotechnology new drugs. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2009-11-27. The firm primarily provides UV-proof active ingredients series products, vitamin D derivative series products, anti-inflammatory analgesic series products, steroid, anti-cancer drugs, cholesterol phosphate binding agents, nuclear magnetic resonance (NMR) reagents, respiratory disease drugs, central nervous system drugs, immune system regulators and weight loss drugs, as well as customized research and development and original equipment manufacturing (OEM) services. The firm distributes its products to Europe, the Americas, Asia and other markets.
